/
LEXX
$0.57+$0.04 (+7.30%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$13.1M
25M shares
52-week range
$0.46 – $1.55
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-6.38
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $433.3K | $222.6K | $384.5K | $722.7K | $255.4K | $226.2K | $464.3K | $705.9K |
| Cost of revenue | $25.2K | $22.9K | $99.4K | $175.3K | $71.8K | $31.5K | $4.8K | $2.7K |
| Gross profit | $408.1K | $199.7K | $215.4K | $547.4K | $183.6K | $194.7K | $459.5K | $703.2K |
| Gross margin | 94.2% | 89.7% | 56.0% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| R&D | $492.9K | $555.7K | $387.1K | $1.3M | $1.8M | $3.7M | $2.4M | $8.2M |
| Operating income | −$6.6M | −$4.1M | −$4.1M | −$5.7M | −$6.6M | −$6.5M | −$5.8M | −$11.9M |
| EBITDA | −$6.6M | −$4.0M | −$4.0M | −$4.0M | −$7.3M | −$6.6M | −$5.7M | −$11.8M |
| Net income | −$6.6M | −$4.1M | −$3.9M | −$4.0M | −$7.3M | −$6.7M | −$5.8M | −$11.9M |
| Net margin | -1523.0% | -1841.5% | -1023.0% | -557.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
| EPS (diluted) | -2.79 | -1.62 | -1.42 | -0.92 | -1.24 | -1.01 | -0.47 | -0.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $200000 | $-0.26 | $-0.29–$-0.23 | 1 |
| 2027 | $1M | $-0.31 | $-0.35–$-0.27 | 1 |
| 2028 | $2M | $-0.28 | $-0.32–$-0.24 | 1 |
| 2029 | $70M | $1.34 | $1.17–$1.51 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lexaria Bioscience Corp. Common Stock
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
www.lexariabioscience.com- Employees
- 7
- IPO / List date
- Sep 8, 2006
- HQ
- KELOWNA, A1
Held by traders on TradeandTell
No one on the platform currently holds LEXX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,300 | $12.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LEXX yet.
